Shopping Cart
- Remove All
- Your shopping cart is currently empty
Ro 44-3888, the active component of sibrafiban, achieves predictable plasma concentrations when administered orally in its prodrug form, Ro 48-3657. Upon reaching a steady state after the second dose, Ro 44-3888 exhibits concentration-dependent inhibition of platelet aggregation and prolongs bleeding time. These findings suggest that Ro 44-3888 merits further evaluation, especially in patients at high risk of arterial thrombosis and those with acute coronary syndrome, due to its reliable absorption.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | Inquiry | 10-14 weeks | |
50 mg | Inquiry | 10-14 weeks |
Description | Ro 44-3888, the active component of sibrafiban, achieves predictable plasma concentrations when administered orally in its prodrug form, Ro 48-3657. Upon reaching a steady state after the second dose, Ro 44-3888 exhibits concentration-dependent inhibition of platelet aggregation and prolongs bleeding time. These findings suggest that Ro 44-3888 merits further evaluation, especially in patients at high risk of arterial thrombosis and those with acute coronary syndrome, due to its reliable absorption. |
Alias | RO-44-3888, RO443888 |
Molecular Weight | 376.41 |
Formula | C18H24N4O5 |
Cas No. | 144412-18-0 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.